- Home
- FLYE vs IMRN Comparison
FLYE vs IMRN Comparison
Compare FLYE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | IMRN |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 7.7M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FLYE | IMRN |
|---|---|---|
| Price | $2.26 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 16.7K |
| Earning Date | 12-17-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,063,357.00 | N/A |
| Revenue This Year | N/A | $16.39 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $0.68 |
| 52 Week High | $109.00 | $1.99 |
Technical Indicators
Market Signals| Indicator | FLYE | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 33.29 |
| Support Level | $1.65 | $0.73 |
| Resistance Level | $2.29 | $0.89 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 47.41 | 27.32 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. It offers 27 E-motorcycle products, 37 E-bike products and 38 E-scooter products.
About IMRN Immuron Limited
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.